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Background: Individuals with chronic lung disease are more susceptible to present reduction in exercise tolerance and
muscles strength not only due to pulmonary limitations but also due systemic repercussions of the pulmonary disease.
The aim of this study is to assess the physical capacity, peripheral muscle function, physical activity in daily life, and the
inflammatory markers in children and adolescents with asthma after pulmonary rehabilitation program.
Method: This is a study protocol of randomized controlled trial in asthmatic patients between 6 to 18 years old. The
assessments will be conducted in three different days and will be performed at the beginning and at the end of the
protocol. First visit: quality of life questionnaire, asthma control questionnaire, pre- and post-bronchodilator spirometry
(400 μcg salbutamol), inflammatory assessment (blood collection), and cardiopulmonary exercise test on a cycle ergometer
to determine aerobic capacity. Second visit: assessment of strength and endurance of the quadriceps femoris and biceps
brachii muscles with concomitant electromyography to assess peripheral muscle strength. Third visit: incremental shuttle
walk test (ISWT) and accelerometer to evaluate functional capacity and physical activity in daily life during 7 days. Then, the
volunteers will be randomized to receive pulmonary rehabilitation program (intervention group) or chest physiotherapy +
stretching exercises (control group). Both groups will have a supervised session, twice a week, each session will have
60 minutes duration, with minimum interval of 24 hours, for a period of 8 weeks. Intervention group: aerobic training
(35 minutes) intensity between 60 to 80 % of the maximum workload of cardiopulmonary exercise testing or of ISWT;
strength muscle training will be applied to the quadriceps femoris, biceps brachii and deltoid muscles (intensity: 40 to 70 %
of maximal repetition, 3 x 8 repetition); finally the oral high-frequency oscillation device (Flutter®) will be used for 5 minutes.
The control group: oral high-frequency oscillation device (Flutter®) for 10 minutes followed by the stretching of upper and
lower limbs for 40 minutes. It is expected to observe the improvement in aerobic capacity, physical activity in daily life,
muscle strength and quality of life of patients in the intervention group, and reduction in inflammatory markers.
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Asthma is one of the main chronic diseases in childhood.
It is characterized by inflammation of the airways [1]. Indi-
viduals with chronic lung disease are more susceptible to
present reduction in exercise tolerance, not only due to
ventilatory constraints, but also due to systemic manifesta-
tions of pulmonary disease [2]. Thus, the more severe and
the less controlled the disease, the higher the dyspnea and
fatigue reported by patients. In general, the obstruction in-
creases the airways resistance, hindering the physiological
ventilatory response during physical exertion and leading
to dyspnea [2]. This in turn leads to the patient having a
more sedentary lifestyle, predisposing them to early fatigue
and exercise intolerance.
Cardiopulmonary exercise testing (CPET) is the gold
standard for determining exercise intolerance [3, 4].
As it is a high-cost assessment, few studies have used
CPET as a method to evaluate asthmatic children and
adolescents [5–9]. Villa and colleagues [6] described the
reduction of oxygen uptake (VO2peak ) in patients with
moderate/severe asthma when compared to the control
group. The same was observed by an English group that
found VO2max reduction in the asthmatic group [7, 8].
Those authors proposed that asthma severity could be an
important factor in determining aerobic capacity. Some
limitations were observed in those mentioned studies, such
as not measuring asthma control (a factor that may influ-
ence the patient’s condition), the small number of assessed
individuals, and not determining the corticosteroid dose
used by patients with asthma.
Clinical field tests are a less expensive alternative to
CPET in determining functional capacity. The incremental
shuttle walking test (ISWT) is a simple and inexpensive
test described by Singh and colleagues [10]. Several authors
using ISWTassessment found a reduction in the functional
capacity of adults with chronic lung disease and its ass-
ociation with lung function and quality of life [11–13]. To
our knowledge, only Ahmaidi and colleagues [14] have
used the run shuttle walk test in pediatric patients with
asthma to determine their functional capacity by compar-
ing with CPET.
Reduction in peripheral muscle strength has been de-
scribed in patients with cystic fibrosis [15] and asthma [6],
and the hypothesis for that is that it is due to sedentary
lifestyle, the chronic use of medication, and systemic in-
flammation. To our knowledge, there are no studies evalu-
ating muscle strength and peripheral muscle endurance
by using electromyography in asthmatic children.
Some studies have had interesting results in cardiopul-
monary conditions, quality of life, and reduction in the
number of hospitalizations after a pulmonary rehabilitation
program in asthmatic children and adolescents [14, 16–23].
Wanrooij and colleagues [24] carried out a systematic
review of physical training with asthmatic children andadolescents, and concluded that physical activity should
be recommended to this population, although some
issues have not yet been clarified due to limitations in
the clinical trials. The control of the disease has not
been addressed by specific questionnaires in any study.
The assessment of inflammatory markers has rarely
been addressed [21], neither has quality of life after
physical training [20, 21].
Hence, the current study aims to assess physical cap-
acity, peripheral muscle function, physical activity in
daily life, quality of life, and inflammatory markers in
children and adolescents with asthma, after undergoing
a pulmonary rehabilitation program.
Methods
Study design
This is a randomized clinical trial to be conducted in the
pulmonary rehabilitation laboratory at University Nove de
Julho. Clinically diagnosed asthmatic patients will be re-
cruited in the Allergy, Clinical Immunology and Rheuma-
tology Clinic at the Department of Pediatrics of Sao Paulo
School of Medicine, Federal University of Sao Paulo. The
individuals will be enrolled in the study after their legal
guardians have read, agreed to, and signed the informed
consent form. The current project was approved by the
Associacao Educacional Nove de Julho Ethical Committee,
Sao Paulo, Brazil, number 738192/2014.
The study will include patients diagnosed with asthma,
between 6 and 18 years old, who are under medical
treatment and disease control according to the Global
Initiative for Asthma (GINA) criteria [1]. Those who fail
to carry out the protocol evaluations, who interrupt
medical care and/or drug-based treatment, who present
with acute lung infection, other chronic lung diseases, or
other comorbidities (neuropathies, heart disease), and
those who miss more than 20 % of the rehabilitation ses-
sions will be excluded from the study.
Outcomes
The primary outcome will be the physical capacity
assessed by the cardiopulmonary exercise testing and
ISWT. The secondary outcomes will be quality of life,
peripheral muscle strength, and inflammatory markers.
Assessments
Questionnaires
The pediatric asthma quality of life questionnaire (PAQLq)
[25] will be used. It is composed of 23 questions divided
into three domains: physical activity limitations (5 ques-
tions), symptoms (10 questions) and emotions (8 ques-
tions). The responses will be measured using a 7-point
scale, according to which 1 indicates the maximum loss
and 7 indicates no loss.
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be applied according to the patient's age [26] to determine
whether asthma is controlled. The ACT consists of five
questions. The scores of each question range between 1
and 5 points. The questionnaire minimum score is 5 points
and the maximum score is 25 points. The C-ACT, which
will be applied to children under 11 years and 12 months,
consists of seven questions, four of them answered by the
children and three by the parents/guardians, with a mini-
mum score of 0 and maximum of 27.
Pulmonary function
Spirometry tests will be performed using ULTIMA CPX
equipment (MedGraphics Corporation®, St Paul, MN,
USA). The technical procedures, acceptance criteria and re-
producibility will be adopted according to recommenda-
tions [27]. All patients will perform the maneuvers post
bronchodilation (salbutamol 400 μcg). The following vari-
ables will be recorded: forced vital capacity (FVC), forced
expiratory volume at the first second (FEV1), FEV1/FVC
ratio and forced expiratory flow (FEF25-75) [28].
Cardiopulmonary exercise testing
The exercise test will be performed in an electromagnetic
braking cycle ergometer (Corival®, LODE BV Medical
Technology, Groningen, Netherlands) connected to a sys-
tem composed of gas exchange and ventilatory variables be-
ing analyzed breath by breath (Breeze CardiO2 System®
microcomputer; Medical Graphics Corporation-MGC, St
Paul, MN, USA). After 2 minutes of freewheel load, the
load will be increased (5 to 20 watts/minute) and the test
will be limited between 8 and 12 minutes [29, 30]. The
following measurements will be analyzed: oxygen
consumption (VO2, mL min
−1) and carbon dioxide
production (VCO2, mL.min), minute ventilation (VE,
L/minute), tidal volume (TV) (mL), respiratory rate (f )
(respirations/minute), and ventilatory equivalents for
O2 and CO2 (VE/VO2, VE/VCO2). The heart rate (HR),
pulse oxyhemoglobin saturation (SpO2) will be con-
tinuously recorded. Blood pressure (BP) will be mea-
sured every 2 minutes of exercise. Dyspnea (Borg D)
and lower limb fatigue (Borg LL) perception scores will
be assessed by using the modified Borg scale [31], with
the patient at rest and immediately after the exercise
cessation. The test will be interrupted by the child or
adolescent due to intolerable dyspnoea and/or fatigue
making it impossible to progress the workload. On the
other hand, the test will be stopped if SpO2 is ≤82 %, or
if patients have cardiac arrhythmias or abnormal blood
pressure response.
Incremental shuttle walking test (ISWT)
The ISWT will be held in a 10-m-long corridor according
to the original description [10]. It is a test externallycadenced by an audible signal, in which the speed increases
every minute ranging from 1.79 to 10.2 Km/h. The test
comes to the end when the patient is not able to reach the
cone two consecutive times, or the patient needs to stop
the test due to fatigue or breathlessness, or SpO2 falls
below 82 %. The tests will be performed twice on the same
day, with a 30-minute break between them. Heart rate,
blood pressure, and Borg fatigue and Borg dyspnea will be
evaluated at the beginning and at the end of the test. The
total test time and the distance walked by the patient will
be recorded at the end of the test.
Physical activity in daily life
Each patient will be monitored by an ActiGraph
accelerometer (GT3X) throughout seven consecutive
days [32]. The accelerometer will be firmly placed on
the patient’s hip (pelvic girdle), and it will be removed
just for sleeping, bathing and swimming. Each indi-
vidual or his/her guardian will be given a form for the
daily descriptions of unusual activities performed while
using the device. The form must be completed at the
end of the day. The number of steps will be recorded
for analysis.
Skeletal muscle function assessment
The maximum isometric voluntary contraction (MIVC)
of the quadriceps femoris (QF) muscle will be obtained
by having the individuals sit on a leg extension machine
(Carci®, São Paulo, Brazil) with their knees positioned
at 60 ° flexion. An inelastic cable connected to a load
cell and adapted to an anklet (EMG System model
EMG800C, São José dos Campos, Brazil) will be posi-
tioned perpendicular to the non-dominant lower limb.
This cell will capture the muscle tension developed
during knee extension MIVC and it will record the
force (Kgf ).
The MIVC of the biceps brachii (BB) muscle will be
obtained by having the individuals sit on a chair. The
same equipment will be connected to a load cell and it
will be positioned perpendicular to the non-dominant
upper limb. This cell will capture the muscle tension de-
veloped during the MIVC of elbow flexion and record it
on the computer.
Three replicates will be held for 5 seconds, with a 1-
minute rest interval between all the measures [33]. The
greatest value of these three contractions of QF and BB
will be considered as the MIVC.
After a resting period of five minutes, the isometric
endurance test (IET) of the QF will be evaluated by the
isometric endurance time at 60 % of the MIVC until the
limit of tolerance (Tlim). The isometric endurance test
will be finished when a 10 % drop of the produced force
occurs. The same procedure will be used to verify the
endurance of the IET by BB. All measurements will be
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Dyspnea and leg fatigue will be evaluated before and im-
mediately after the test by the modified Borg scale. This
test will take approximately 15 minutes.Surface electromyography (sEMG)
The surface electromyographic (sEMG) will be re-
corded in the dominant upper and lower limb. Active
bipolar surface electrodes will be positioned in the belly
of the evaluated muscles (RF and BB) as previously
described [34]. The sEMG (EMG System, model
EMG800C, São José dos Campos, Brazil) will be re-
corded using a 4-channel device (EMG System do
Brazil Ltda®), with a band pass filter with cutoff fre-
quencies of 20 to 500 Hz, an amplifier gain of 1000,
and a common rejection mode ratio >100 dB. All data
will be acquired and processed using a 12-bit analog-
to-digital converter, with a sampling frequency of 2
kHz. The obtained signal will be amplified and con-
verted to digital format for data recording and analysis.
The sEMG signal will be divided into 1-second windows
and the root mean square (RMS) and median frequency
(MDF) of the power spectrum will be calculated for each
window. Five consecutive values over RMS time and MDF
will be averaged to obtain mean values corresponding
to 0, 25, 50, 75, and 100 % of the endurance time. All
EMG signals will be processed performing specific rou-
tines carried out in the Matlab program, R2010b (The
MathWorks Inc., Natick, MA, USA).Inflammatory markers
Blood IL-4, IL-5, IL-10, IL-13, PCR, and TNFα will be
assessed [35]. The plasma will be centrifuged for 10
minutes at 3,000 rpm in a centrifuge refrigerated at 0
to 4 °C (Eppendorf, 5804-R), and the supernatant will
be frozen in a freezer at −80 °C for dosing. Dosing of
cytokines and TNFα will be performed in plasma, in
microplates (96 wells) sensitized with the antibody to
the protein of interest, adhered to the wall of the
plate wells by an immunoadsorbent substrate. The
following human-specific kits will be used: human
TNFα ELISA kit, human IL-4, IL-5 ELISA kit, human
IL-10, and human IL-13 ELISA kit.Protocol
The assessments will be conducted in three visits, as de-
scribed below (Fig. 1).
Visit 1: quality of life questionnaire, asthma control
questionnaire, pre- and post-bronchodilator spirometry
(400 μcg salbutamol), inflammatory assessment (blood
collection), and cardiopulmonary exercise test on a cycle
ergometer.Visit 2: Assessment of strength and endurance of the
quadriceps femoris and biceps brachii muscles with sur-
face electromyography.
Visit 3: ISWT and an accelerometer will be used to as-
sess physical activity in daily life.
The volunteers will be randomized to receive a pulmon-
ary rehabilitation program (intervention group) or chest
physiotherapy plus stretching exercises (control group), as
described below by the website randomization.com.Intervention group
The intervention group will have a supervised rehabilita-
tion program held twice a week. Each session will be 60
minutes in duration, with a minimum interval of 24 hours,
for a period of 8 weeks. Each session will consist of three
parts: aerobic training, strength muscle training, and chest
physiotherapy. The aerobic training will be held for 35 mi-
nutes (10 minutes of warm up, 20 minutes on target load,
and 5 minutes of cooling down) with an initial intensity of
60 % of the maximum load obtained in the maximal car-
diopulmonary exercise testing or in the ISWT. The inten-
sity will be gradually increased up to 80 %, so that fatigue
or dyspnea values are kept between 4 and 6, according to
the modified Borg scale [31]. When necessary, supplemen-
tal oxygen will be supplied during training to keep oxygen
saturation greater than 92 %. Strength muscle training will
be applied to the quadriceps femoris, biceps brachii, and
deltoid muscles for 15 minutes. The intensity will be 40 to
70 % of maximal repetition (1 MR) in three sets of eight
repetitions. Finally, for chest physiotherapy, the oral high-
frequency oscillation device (Flutter®) will be used for 5 mi-
nutes. The volunteers in this group will receive a 200-μcg
bronchodilator before starting the session each day.Control group
The control group will have chest physiotherapy and
stretching exercises twice a week. Each session will be
60 minutes, with a minimum interval of 24 hours, for a
period of 8 weeks. For each session, the oral high-
frequency oscillation device (Flutter®) will be used for 10
minutes, 5 minutes in each lateral decubitus position,
followed by stretching of the upper and lower limbs for
40 minutes. All exercises will be active, performed in sit-
ting and lying positions without increasing the heart
rate. The remaining 10 minutes will be used to discuss
doubts about the disease and the use of the booklet.
Both groups will be oriented about the disease (proper
use of medication, use of peak flow, triggering factors for
crisis). On the date of the initial evaluation, they will take
home a booklet with the main information about the given
guidelines. All volunteers will be reevaluated after 8 weeks,
when the same initial assessments will be performed again.
Fig 1 Flow of patients through the study
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The sample size was based on the run shuttle walk test
levels and on the maximum load achieved in CPET
[14]. Considering the stages of the shuttle, and assum-
ing an alpha risk of 5 % and beta risk of 80 %, standard
deviation of 1.6, and a difference in magnitude of 2.0
levels before and after the pulmonary rehabilitation
program [14], the sample size needed was 27 patients
in each group. Considering the load (W) achieved in
the cardiopulmonary exercise testing, with a −3 ± 2 W
difference pre- and post-intervention in the control
group, and of 16 ± 7 [20] in the intervention group,
with an alpha risk of 5 % and a beta risk of 95 %, the
sample size needed was 10 patients in each group.
Therefore, considering potential losses, 30 asthmatic
patients will be recruited for each group, requiring a
total of 66 volunteers.
The data normality will be analyzed using the
Kolmogorov-Smirnov test. Parametric data will be repre-
sented as means (SD) and nonparametric data as medians
(IQR (25th−75th percentiles). Comparisons between
groups and time (pre- and post-rehabilitation) will be ana-
lyzed by two-way analysis of variance (ANOVA), with the
Bonferroni test post hoc, or by the Kruskal Wallis test, de-
pending on the data adherence or non-adherence to the
Gaussian curve. Correlation between variables will be ana-
lyzed by Pearson or Spearman correlation according to
the data distribution. Three-way repeated measures
ANOVA group vs endurance (0–100 % endurance time,
25 % increments time) vs time (pre- and post-) will be
used to assess the dependency of the EMG variables and
will followed by post hoc Student–Newman–Keuls pair-
wise comparisons, when appropriate. The value of P <0.05will be set as significant. SPSS version 13 (Chicago, IL,
USA) will be the statistical software used in the study.
Discussion
Asthma is the most common chronic lung disease in the
pediatric population. The dyspnea sensation during exer-
cise in these patients is secondary to increases in airway
resistance, pulmonary hyperinflation, and hypoxemia ob-
served in severely affected patients [2]. Some studies
have described a reduction in exercise capacity in asth-
matic pediatric patients [5–9]. The main hypothesis is
that this is due to the deconditioning of the patient,
which is a result of the pathogenesis of asthma. The
more severely affected the patient, the greater the
deconditioning. However, some issues have not been
widely addressed to justify the reduction in aerobic cap-
acity: the control of asthma, the severity according to
the Asthma Consensus [1], the amount of medication,
and the level of physical activity.
In addition to the decrease in aerobic capacity, a re-
duction in peripheral muscle strength is observed in
chronic lung disease [6, 15, 36]. Villa et al. [6] described
a reduction in skeletal muscle function in asthmatic pa-
tients. They observed that endurance was lower in the
quadriceps muscle of severe asthmatic patients com-
pared to moderate and intermittent disease. The hypoth-
eses about this muscle restriction are based on the
chronic use of corticosteroids, sedentary lifestyles, and
the reduction in aerobic capacity, but the literature
about muscle strength and endurance in asthmatic
pediatric patients is scarce. More studies must be done
to answer this question, including assessment of the
amount of medication and the level of physical activity.
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or a questionnaire, but the cognitive and physiological
changes can be difficult in this evaluation for a pediatric
population. It can also be evaluated by objective methods
such as an accelerometer, which is the gold standard [37].
The correlation between physical activity and lung function
was first addressed by Pitta et al. [38] in adult patients with
chronic obstructive pulmonary disease. To our knowledge,
physical activity evaluated by accelerometer in pediatric
asthmatic patients has only been reported by Souza et al.
[39]. The group did not observe differences in the number
of steps between the asthma and control groups, but some
asthmatic children were overweight, and the group did not
evaluate teenagers.
Pulmonary rehabilitation is recommended for patients
with chronic lung disease with reduction in aerobic cap-
acity and muscle strength [40]. It was described in two
systematic reviews of asthmatic pediatric patients that
exercise training reduces the risk of exacerbation,
exercise-induced bronchospasm, and increases in quality
of life [24, 41]. However, some issues are not clear about
pulmonary rehabilitation in the pediatric population.
There are different intensities of training described, the
control of asthma has to be well-addressed, muscle
strength and endurance are poorly evaluated, the sever-
ity of disease is not described as determined by consen-
sus [1], physical activity is not usually measured by a
gold standard, and protocols that evaluate inflammatory
markers, such as cytokines are rare [42].
The current study hopes to determine the benefits of
pulmonary rehabilitation in children and adolescents di-
agnosed with asthma, such as improvement in functional
capacity, physical activity in daily life, muscle strength,
quality of life and inflammatory markers. Thus, we will
have greater support in the use of physical exercise in
the asthmatic pediatric population.
Trial status
Patient are been recruited at the time of submission.
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